Tag: Pnh

Overactive complement system activity is a primary driver of several rare autoimmune diseases. For individuals with these challenging conditions, understanding *why do you take Ultomiris* is crucial to managing symptoms, preventing organ damage, and improving quality of life. This long-acting medication specifically targets a key protein in this immune pathway to provide sustained disease control.

Approximately 85% of generalized myasthenia gravis cases are driven by an immune system attack, highlighting the role of complement inhibitors like Eculizumab and avacopan. What is the difference between Eculizumab and avacopan, and how do their targeted actions impact treatment for various autoimmune conditions?

Without treatment from complement inhibitors, the 10-year survival rate for patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) is just 65% [1.3.3]. Eculizumab revolutionized treatment for this and other rare diseases. But **how does Eculizumab work** to achieve this?

Crovalimab is a novel anti-C5 monoclonal antibody approved to treat paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder characterized by complement-mediated red blood cell destruction. Its mechanism of action involves a unique recycling technology that enhances its efficiency and allows for convenient subcutaneous dosing every four weeks.